Know Cancer

or
forgot password

A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma


Phase 2
18 Years
N/A
Not Enrolling
Both
Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma

Thank you

Trial Information

A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma


Light Infusion Technology (Litx™) is a locoregional cancer treatment in which a systemically
administered light-activated drug (LS11) is activated locally by illuminating the diseased
tissue using light-emitting diodes (LEDs) of a specific wavelength. The activated
photosensitizer reacts with endogenous oxygen to yield highly reactive species of oxygen
that cause destruction of cellular structures such as mitochondria, lysosomes and cell walls
leading to irreversible cell damage and tissue death.

Either twenty-four or twelve hours prior to surgery, the patient will receive an intravenous
dose of 1 mg/kg of LS11, given IV by slow push over 3-5 minutes.

Following craniotomy, patients will undergo intraoperative placement of a single Light
Source, centrally placed within the tumor, under direct visualization prior to tumor
resection. Following placement of the light source (with the depth of the end of the light
bar from the cortical surface to be calculated from the pre-operative MRI and spiral CT
scan, so as to be centralized within the main tumor bulk), light will be delivered following
a predetermined escalation schedule (either 100 J/cm or 200 J/cm) at 20 mW/cm light energy
for a treatment time of 1 hour 24 minutes (100J/cm) or 2 hours 46 minutes (200 J/cm). The
Light Source will then be manually removed and the tumor maximally resected.

The resected tumor and marginal tissue will be submitted for pathology to determine depth of
cell death, extent of tumor tissue containing closed vessels, any evidence of vessel closure
or other damage to tissues outside of the projected kill zone.


Inclusion Criteria:



- Have primary or recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma
(AA) undergoing planned tumor resection

- Have a right sided, supratentorial frontal or temporal lobe tumor

- Have right hand dominance

- Be adults aged >18 years

- Have a Karnofsky Performance Status score >70

- Have a estimated life expectancy of >12 weeks

- Have completed any prior antineoplastic therapy at least 4 weeks prior to surgery and
be recovered from acute side effects

- Must have the understanding and ability to sign an informed consent document

- Be male or non-pregnant, non-lactating females. Patients who are fertile must agree
to use an effective method of contraception during participation in the study

- Have a negative serum or urine pregnancy test within 14 days prior to treatment (if
patient is a female of childbearing potential).

Exclusion Criteria:

Patients must be excluded if any of the following apply:

- Have tumors <2 cm in diameter

- Have inadequate organ function as evidenced by: PT or PTT >1.5 × control ; Platelet
count <100,000/mm3 ; WBC <2,500/mm3 ; Neutrophils <2000/mm3 ; Hemoglobin <9 g/dL

- Be concurrently participating in another clinical trial involving experimental
treatment

- Have any concurrent diseases or conditions that in the opinion of the investigator
impair the patient's ability to complete the trial such as psychological, familial,
sociological, geographical or medical conditions which in the Principal
Investigator's opinion could compromise compliance with the objectives and procedures
of this protocol or obscure interpretation of the trial's data are excluded.

- Have psychological, familial, sociological, geographical, or medical conditions
which, in the Investigator's opinion, could compromise compliance with the objectives
and procedures of this protocol or obscure interpretation of the trial data.

- Have a known sensitivity to porphyrin-type drugs or known history of porphyria

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma

Principal Investigator

Sy-Shi Wang, PhD

Investigator Role:

Study Director

Investigator Affiliation:

Light Sciences Oncology

Authority:

Serbia: Serbian Drug Agency

Study ID:

LSO-OL007

NCT ID:

NCT00409214

Start Date:

November 2006

Completion Date:

Related Keywords:

  • Glioma
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Glioma
  • Litx™
  • LS11
  • Glioblastoma multiforme
  • Anaplastic Astrocytoma
  • GBM
  • AA
  • Astrocytoma
  • Glioblastoma
  • Glioma

Name

Location